Ikonisys Announces the Successfull Installation of the Ikoniscope20 at TomaLab, One of the Largest Genetic Laboratories in Italy
07 Février 2022 - 6:50PM
Business Wire
- The Ikoniscope20 has been successfully installed at Toma
Advanced Biomedical Assays and being used for daily workflow for
the patient care
- TomaLab will act as a Reference Laboratory for Ikonisys,
boosting R&D and commercialization opportunities
- Future applications for novel tests are under evaluation, to
further exploit the capabilities of the instrument to automate
laboratory workflow and analyze samples otherwise impossible to
investigate manually
Regulatory News:
Ikonisys SA (Code ISIN: FR00140048X2 / Mnémonique:
ALIKO), a company specializing in the early and accurate
detection of cancer with a unique fully-automated solution for
medical diagnostic labs, announced the successful sale and
installation of the Ikoniscope20 at Toma Advanced Biomedical Assays
Spa (Busto Arsizio, VA, Italy) and the continuation of the
productive collaboration between the laboratory and the company.
Since the installation, TomaLab has been successfully validating
the Ikoniscope20 for routine FISH testing in oncology, using
several applications that span from lung cancer (oncoFISH ALK) to
bladder cancer (oncoFISH bladder).
The partnership is a concrete milestone for the marketing
strategy and demonstrates the ability of the sales organization to
achieve the objective of rapid growth of Ikoniscope20
installations: TomaLab will act as a reference laboratory for
Ikonisys, allowing interested stakeholders and prospects to review
the instrument and its capabilities.
The laboratory will continue to collaborate in the development
of novel applications for tests that are becoming or will become of
particular interest in the field of cancer diagnostics, with a
particular regard to the capabilities of the instrument to perform
both FISH-based and antibody-based tests. This is a factual step in
the strategy mentioned at IPO to develop new applications,
expanding into new promising segments of the IVD market.
Dr. Tshering Dorji, Head of Pathology, TomaLab,
commented, “We are highly impressed by the Ikoniscope20 and pleased
to continue our collaboration with Ikonisys. The instrument’s
compact size allowed us to install it flawlessly in our facility
and the high throughput of this new FISH analyzer is very
impressive. Combined with the high quality of the scanned images
reported and the easy-to-use remote connection, the instrument
continues to play a very important role in our daily workflow for
the patient care.”
Michael Kilpatrick, Chief Scientific Officer of Ikonisys,
added “We are honored and thrilled to continue working with a
leading European laboratory such as TomaLab. This, in our opinion,
certifies the hard work that was put into the development of the
new instrument in order to meet and exceed customers’ expectations.
The collaboration with TomaLab has already allowed us to develop
new applications in the past and we’re looking forward to the
excellent ideas that might come from the discussion with such a
sophisticated customer, to expand our product portfolio in FISH and
other segments. We believe that in the short term this will allow
us to add new applications for detection of genetic aberrations in
several tissue types, whilst continuing to utilize the capabilities
of the platform to develop tests based on the combined analysis of
genes and proteins.”
Jurgen Schipper, Chief Commercial Officer of Ikonisys
concluded: “The fact that TomaLab will act as a first reference lab
for us represents an important support as we continue our expansion
in the European market. After the recent hiring of our experienced
Sales Director for France, this is another important brick in the
construction of our sales strategy, based on initial sales to Key
Opinion leaders and highly respected customers, that will act as
sponsors for our innovative instrument and applications.”
About Ikonisys
Ikonisys SA is a cell-based diagnostics company based in Paris
(France), New Haven (Connecticut, USA) and Milan (Italy)
specialized in the early and accurate detection of cancer. The
company develops, produces and markets the proprietary
Ikoniscope20® platform, a fully-automated solution designed to
deliver accurate and reliable detection and analysis of rare and
very rare cells. Ikonisys has received FDA clearance for several
automated diagnostic applications, which are also marketed in
Europe under CE certification. Through its breakthrough
fluorescence microscopy platform, the company continues to develop
a stream of new tests, including liquid biopsy tests based on
Circulating Tumor Cells (CTC).
For further information, please go to www.Ikonisys.com
Disclaimer
This press release contains forward-looking statements about the
Company's prospects and development. These statements are sometimes
identified by the use of the future tense, the conditional tense
and forward-looking words such as "believe", "aim to", "expect",
"intend", "estimate", "believe", "should", "could", "would" or
"will" or, where appropriate, the negative of these terms or any
other similar variants or expressions. This information is not
historical data and should not be construed as a guarantee that the
facts and data set forth will occur. This information is based on
data, assumptions and estimates considered reasonable by the
Company. It is subject to change or modification due to
uncertainties relating to the economic, financial, competitive and
regulatory environment. This information contains data relating to
the Company's intentions, estimates and objectives concerning, in
particular, the market, strategy, growth, results, financial
situation and cash flow of the Company. The forward-looking
information contained in this press release is made only as of the
date of this press release. The Company does not undertake to
update any forward-looking information contained in this press
release, except as required by applicable law or regulation. The
Company operates in a competitive and rapidly changing environment
and therefore cannot anticipate all of the risks, uncertainties or
other factors that may affect its business, their potential impact
on its business or the extent to which the materialization of any
one risk or combination of risks could cause results to differ
materially from those expressed in any forward-looking information,
it being recalled that none of this forward-looking information
constitutes a guarantee of actual results.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220207005776/en/
Ikonisys Alessandro Mauri CFO investors@ikonisys.com
NewCap Olivier Bricaud / Louis-Victor Delouvrier Investor
Relations Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 92
NewCap Nicolas Merigeau Media Relations
Ikonisys@newcap.eu Tel.: +33 (0)1 44 71 94 98
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ikonisys (EU:ALIKO)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024